Investors
Contact

North America

South America

Asia

Middle East

Africa

Australia

Europe

Pipeline

Gilead’s research and development program identifies and evaluates investigational compounds that show potential to advance the treatment of life-threatening diseases in areas of unmet medical need.

Pipeline

HIV / AIDS

Gilead is committed to pursuing innovation in HIV across the spectrum of care. We are working to address remaining needs in both prevention and treatment. And, we are focused on discovery research that could potentially, one day, lead to a cure.

The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

  • Emtricitabine and tenofovir alafenamide

    Potential Indication: PrEP

    Phase 1
    Phase 2
    Phase 3
  • GS-9131 (NRTI)

    Potential Indication: HIV/AIDS

    Phase 1
    Phase 2
    Phase 3
  • GS-6207 (Capsid Inhibitor)

    Potential Indication: HIV/AIDS

    Phase 1
    Phase 2
    Phase 3
  • Vesatolimod (TLR-7 agonist)

    Potential Indication: HIV/AIDS

    Phase 1
    Phase 2
    Phase 3
  • GS-9722 (bNab)

    Potential Indication: HIV/AIDS

    Phase 1
    Phase 2
    Phase 3

Liver Diseases

Gilead’s liver disease research focuses on investigating medicines for patients with advanced fibrosis due to nonalcoholic steatohepatitis (NASH) and for potentially curing patients chronically infected with the hepatitis B virus (HBV).

The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

  • GS-9688 (TLR-8 agonist)

    Potential Indication: HBV

    Phase 1
    Phase 2
    Phase 3
  • Selonsertib (ASK-1 inhibitor)

    Potential Indication: NASH

    Phase 1
    Phase 2
    Phase 3
  • GS-9674 (FXR agonist)

    Potential Indication: NASH

    Phase 1
    Phase 2
    Phase 3
  • GS-9674 (FXR agonist)

    Potential Indication: Primary Biliary Cirrhosis

    Phase 1
    Phase 2
    Phase 3
  • GS-9674 (FXR agonist)

    Potential Indication: Primary Sclerosing Cholangitis

    Phase 1
    Phase 2
    Phase 3
  • GS-0976 (ACC Inhibitor)

    Potential Indication: NASH

    Phase 1
    Phase 2
    Phase 3

Hematology / Oncology

Gilead is advancing a pipeline of cancer therapies in the areas of cell therapy, immuno-oncology and targeted therapies. Following the 2017 acquisition of Kite Pharma, Inc., our leading cell therapy pipeline now includes investigational cell therapies and next-generation technologies for a range of hematologic malignancies and solid tumors.

The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

  • Axicabtagene ciloleucel

    Trial: ZUMA-5 Potential Indication: Indolent NHL

    Phase 1
    Phase 2
    Phase 3
  • Axicabtagene ciloleucel

    Trial: ZUMA-6 Potential Indication: DLBCL (PD-L1 mAb)

    Phase 1
    Phase 2
    Phase 3
  • Axicabtagene ciloleucel

    Trial: ZUMA-7 Potential Indication: 2nd line DLBCL

    Phase 1
    Phase 2
    Phase 3
  • KTE-X19

    Trial: ZUMA-2 Potential Indication: MCL

    Phase 1
    Phase 2
    Phase 3
  • KTE-X19

    Trial: ZUMA-3 Potential Indication: Adult ALL

    Phase 1
    Phase 2
    Phase 3
  • KTE-X19

    Trial: ZUMA-4 Potential Indication: Pediatric ALL

    Phase 1
    Phase 2
    Phase 3
  • KITE-585 (anti-BCMA)

    Potential Indication: MM

    Phase 1
    Phase 2
    Phase 3
  • KITE-718 (MAGE A3/A6)

    Potential Indication: Solid Tumor

    Phase 1
    Phase 2
    Phase 3
  • Tirabrutinib (BTK inhibitor)

    Potential Indication: B-cell malignancies

    Phase 1
    Phase 2
    Phase 3

Inflammation / Respiratory

Gilead is advancing a pipeline of novel investigational agents for inflammatory diseases, addressing multiple targets with potential application across a broad range of disorders.

The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

  • Filgotinib (JAK1 inhibitor)

    Potential Indication: Rheumatoid Arthritis

    Phase 1
    Phase 2
    Phase 3
  • Filgotinib (JAK1 inhibitor)

    Potential Indication: Crohn's Disease

    Phase 1
    Phase 2
    Phase 3
  • Filgotinib (JAK1 inhibitor)

    Potential Indication: Ulcerative Colitis

    Phase 1
    Phase 2
    Phase 3
  • Filgotinib (JAK1 inhibitor)

    Potential Indication: Inflammatory Diseases

    Phase 1
    Phase 2
    Phase 3
  • Presatovir (fusion inhibitor)

    Potential Indication: Respiratory Syncytial Virus

    Phase 1
    Phase 2
    Phase 3
  • GS-9876 (Syk inhibitor)

    Potential Indication: Sjogren’s Syndrome

    Phase 1
    Phase 2
    Phase 3
  • GS-9876 (Syk inhibitor)

    Potential Indication: Lupus

    Phase 1
    Phase 2
    Phase 3
  • GS-4875 (TPL2 inhibitor)

    Potential Indication: Inflammatory Bowel Disease

    Phase 1
    Phase 2
    Phase 3

Other

Gilead is collaborating with U.S. Department of Defense, Centers for Disease Control and Prevention, and National Institutes of Health as well as multiple academic institutions to discover and develop novel antivirals for highly pathogenic infections and neglected/emerging viral diseases, including Ebola.

The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

  • Remdesivir (GS-5734, Nuc inhibitor)

    Potential Indication: Ebola Virus Infection

    Phase 1
    Phase 2
    Phase 3